Tag: share

REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the “Offering”) of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deducting the underwriting discounts and commissions and offering expenses, the aggregate gross proceeds to the Company were approximately $98 million.

Publicity Department of Shenyang Municipal Party Committee

Sydney, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Australian superannuation regulations require self-managed super funds to maintain a documented investment strategy that covers asset allocation, liquidity, diversification, and both income and capital objectives. The Australian Taxation Office mandates that the strategy be reviewed at least annually. For trustees building that strategy around delivering monthly income, the income side of the portfolio will be reviewed closely. The latest ATO data shows the SMSF sector now holds A$1.06 trillion in assets across 663,867 funds, with cash and term deposit allocations falling to 16.3% of holdings, a record low, as trustees look beyond traditional cash products. To learn mroe visit https://termplus.com.au/term-account-smsf/

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Ear Health Market size & share revenue was valued at approximately USD 10.12 Billion in 2025 and is expected to reach USD 10.82 Billion in 2026 and is expected to reach around USD 16.87 Billion by 2035, at a CAGR of 5.7% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Sonova Holdings AG, GN Store Nord A/S, William Demant Holdings A/S, Starkey Laboratories Inc., WS Audiology, Cochlear Limited, MED-EL, Eargo Inc., Audina Hearing Instruments Inc., Rion Co. Ltd and others.

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Fluorescent In Situ Hybridization Probe Market size & share revenue was valued at approximately USD 1.14 Billion in 2025 and is expected to reach USD 1.23 Billion in 2026 and is expected to reach around USD 2.27 Billion by 2035, at a CAGR of 7.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scientific Inc., Abbott Laboratories, Agilent Technologies Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Bio-Rad Laboratories Inc., Oxford Gene Technology (Sysmex), Abnova Corporation, Empire Genomics LLC, MetaSystems Group and others.

Miami, FL, June 17, 2026 (GLOBE NEWSWIRE) -- Collective Acquisition Corp. II (Nasdaq: CAIIU) (the “Company”) announced today that, commencing June 22, 2026, holders of the units issued in the Company’s initial public offering (the “Units”), each consisting of one Class A ordinary share of the Company (the “Class A Ordinary Shares”) and one-half of one redeemable warrant of the Company (each whole warrant, a “Warrant”), with each whole Warrant entitling the holder thereof to purchase one Class A Ordinary Share at an exercise price of $11.50 per share, may elect to separately trade the Class A Ordinary Shares and Warrants included in the Units. No fractional Warrants will be issued upon separation of the Units and only whole Warrants will trade. The Class A Ordinary Shares and Warrants will trade on the Nasdaq Global Market under the symbols “CAII” and “CAIIW,” respectively. Units not separated will continue to trade on the Nasdaq Global Market under the symbol “CAIIU.”